207 related articles for article (PubMed ID: 28539588)
21. ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity.
Haines BB; Denslow A; Grzesik P; Lee JS; Farkaly T; Hewett J; Wambua D; Kong L; Behera P; Jacques J; Goshert C; Ball M; Colthart A; Finer MH; Hayes MW; Feau S; Kennedy EM; Lerner L; Quéva C
Cancer Immunol Res; 2021 Mar; 9(3):291-308. PubMed ID: 33355229
[TBL] [Abstract][Full Text] [Related]
22. Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy.
Panagioti E; Kurokawa C; Viker K; Ammayappan A; Anderson SK; Sotiriou S; Chatzopoulos K; Ayasoufi K; Johnson AJ; Iankov ID; Galanis E
J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34196308
[TBL] [Abstract][Full Text] [Related]
23. PD-1 blockage delays murine squamous cell carcinoma development.
Belai EB; de Oliveira CE; Gasparoto TH; Ramos RN; Torres SA; Garlet GP; Cavassani KA; Silva JS; Campanelli AP
Carcinogenesis; 2014 Feb; 35(2):424-31. PubMed ID: 24031027
[TBL] [Abstract][Full Text] [Related]
24. Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors.
Omori R; Eguchi J; Hiroishi K; Ishii S; Hiraide A; Sakaki M; Doi H; Kajiwara A; Ito T; Kogo M; Imawari M
Cancer Gene Ther; 2012 Sep; 19(9):637-43. PubMed ID: 22790963
[TBL] [Abstract][Full Text] [Related]
25. Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells.
Farrell CJ; Zaupa C; Barnard Z; Maley J; Martuza RL; Rabkin SD; Curry WT
Clin Cancer Res; 2008 Dec; 14(23):7711-6. PubMed ID: 19047097
[TBL] [Abstract][Full Text] [Related]
26. Systemic CD8+ T cell-mediated tumoricidal effects by intratumoral treatment of oncolytic herpes simplex virus with the agonistic monoclonal antibody for murine glucocorticoid-induced tumor necrosis factor receptor.
Ishihara M; Seo N; Mitsui J; Muraoka D; Tanaka M; Mineno J; Ikeda H; Shiku H
PLoS One; 2014; 9(8):e104669. PubMed ID: 25105508
[TBL] [Abstract][Full Text] [Related]
27. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells.
Wang S; Campos J; Gallotta M; Gong M; Crain C; Naik E; Coffman RL; Guiducci C
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):E7240-E7249. PubMed ID: 27799536
[TBL] [Abstract][Full Text] [Related]
28. Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer.
Crespo-Rodriguez E; Bergerhoff K; Bozhanova G; Foo S; Patin EC; Whittock H; Buus R; Haider S; Muirhead G; Thway K; Newbold K; Coffin RS; Vile RG; Kim D; McLaughlin M; Melcher AA; Harrington KJ; Pedersen M
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32759235
[TBL] [Abstract][Full Text] [Related]
29. T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model.
Liu H; Weber A; Morse J; Kodumudi K; Scott E; Mullinax J; Sarnaik AA; Pilon-Thomas S
PLoS One; 2018; 13(4):e0196033. PubMed ID: 29694419
[TBL] [Abstract][Full Text] [Related]
30. Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model.
Dobson CC; Naing T; Beug ST; Faye MD; Chabot J; St-Jean M; Walker DE; LaCasse EC; Stojdl DF; Korneluk RG; Holcik M
Oncotarget; 2017 Jan; 8(2):3495-3508. PubMed ID: 27966453
[TBL] [Abstract][Full Text] [Related]
31. Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma.
Wirsching HG; Zhang H; Szulzewsky F; Arora S; Grandi P; Cimino PJ; Amankulor N; Campbell JS; McFerrin L; Pattwell SS; Ene C; Hicks A; Ball M; Yan J; Zhang J; Kumasaka D; Pierce RH; Weller M; Finer M; Quéva C; Glorioso JC; Houghton AM; Holland EC
JCI Insight; 2019 Jul; 4(13):. PubMed ID: 31292299
[TBL] [Abstract][Full Text] [Related]
32. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
Mangsbo SM; Sandin LC; Anger K; Korman AJ; Loskog A; Tötterman TH
J Immunother; 2010 Apr; 33(3):225-35. PubMed ID: 20445343
[TBL] [Abstract][Full Text] [Related]
33. Combination immunotherapy of oncolytic virus nanovesicles and PD-1 blockade effectively enhances therapeutic effects and boosts antitumour immune response.
Ji W; Li L; Zhou S; Qiu L; Qian Z; Zhang H; Zhao P
J Drug Target; 2020 Nov; 28(9):982-990. PubMed ID: 32379004
[TBL] [Abstract][Full Text] [Related]
34. PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization.
Rekoske BT; Smith HA; Olson BM; Maricque BB; McNeel DG
Cancer Immunol Res; 2015 Aug; 3(8):946-55. PubMed ID: 26041735
[TBL] [Abstract][Full Text] [Related]
35. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy.
Liu Z; Ravindranathan R; Kalinski P; Guo ZS; Bartlett DL
Nat Commun; 2017 Mar; 8():14754. PubMed ID: 28345650
[TBL] [Abstract][Full Text] [Related]
36. Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy.
Ghonime MG; Saini U; Kelly MC; Roth JC; Wang PY; Chen CY; Miller K; Hernandez-Aguirre I; Kim Y; Mo X; Stanek JR; Cripe T; Mardis E; Cassady KA
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599026
[TBL] [Abstract][Full Text] [Related]
37. Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses.
Beavis PA; Milenkovski N; Henderson MA; John LB; Allard B; Loi S; Kershaw MH; Stagg J; Darcy PK
Cancer Immunol Res; 2015 May; 3(5):506-17. PubMed ID: 25672397
[TBL] [Abstract][Full Text] [Related]
38. Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms.
Kim DS; Dastidar H; Zhang C; Zemp FJ; Lau K; Ernst M; Rakic A; Sikdar S; Rajwani J; Naumenko V; Balce DR; Ewanchuk BW; Tailor P; Yates RM; Jenne C; Gafuik C; Mahoney DJ
Nat Commun; 2017 Aug; 8(1):344. PubMed ID: 28839138
[TBL] [Abstract][Full Text] [Related]
39. Imaging of Activated T Cells as an Early Predictor of Immune Response to Anti-PD-1 Therapy.
Levi J; Lam T; Goth SR; Yaghoubi S; Bates J; Ren G; Jivan S; Huynh TL; Blecha JE; Khattri R; Schmidt KF; Jennings D; VanBrocklin H
Cancer Res; 2019 Jul; 79(13):3455-3465. PubMed ID: 31064845
[TBL] [Abstract][Full Text] [Related]
40. PD-1 Status in CD8
Kansy BA; Concha-Benavente F; Srivastava RM; Jie HB; Shayan G; Lei Y; Moskovitz J; Moy J; Li J; Brandau S; Lang S; Schmitt NC; Freeman GJ; Gooding WE; Clump DA; Ferris RL
Cancer Res; 2017 Nov; 77(22):6353-6364. PubMed ID: 28904066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
